KAN-002 is under clinical development by Kanvas Biosciences and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KAN-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KAN-002 overview
KAN-002 is under development for the treatment of inflammatory bowel disease. It is a live biotherapeutic microbial based therapy.
Kanvas Biosciences overview
Kanvas Biosciences is engaged in developing multiplexed imaging technology for microbial detection for infectious diagnostic disease. The company is headquartered in Middlesex, New Jersey, the US.
For a complete picture of KAN-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.